Space Peptides Pharmaceutical is pleased to welcome Dr. Simon Nebel as Business Advisor.
Dr. Simon Nebel has participated in the financing of a number of life science companies and the M&A transactions for Aravis portfolio companies. Simon has been the board member or observer in fourteen companies. Before joining Aravis, he was a group strategist at UBS. Dr. Nebel got his PhD in Biophysics at the Biocentre of the University of Basel and an MBA from the London Business School.
Space Peptides Pharmaceutical is pleased to welcome Prof. Hans-Joachim Böhm as Scientific advisor.
Prof. Hans-Joachim Böhm is a professor of Bioinformatics at the University of Basel, working on the development of new methods for computer-aided drug design, as well as a member of the Swiss Science Council. He worked for several years at Roche in both Basel and Palo Alto (USA) where he became global head of chemical research. He also worked at Siemens in Munich in the field of microelectronics research and then at BASF in Ludwigshafen in structure-based design of drugs. Prof. Böhm studied chemistry at the University of Karlsruhe where he did both his PhD and his Post Doc.
Space Peptides extends its strategic collaboration with the University of Bern, Switzerland, to the next 5 years
Space Peptides announces that it decided to extend its collaboration with the University of Bern, Switzerland, for the next 5 years, aiming to continue to build on the success of the precedent years of successfully accelerating translational research projects as well as building a strong cohort of scientists with in-depth knowledge of AI-based drug discovery from both the academic and industrial perspective.
Opening ceremony celebrates the construction for Space Peptides of a large-scale peptide manufacturing facility in Jiangsu, China
Space Peptides will invest approximately USD 150 million to build state-of-the-art manufacturing facilities, expanding to an annual capacity of 1100 kg to support scaling of peptide active pharmaceutical ingredient production to clinical and commercial manufacturing, covering therapeutic areas of women’s health, metabolic diseases, antimicrobial and onco-immunology.
The new facility will have an area of approximately 80,000 square meter, with the latest manufacturing technology. Construction of the manufacturing facility is expected to finish in Dec 2022, whereas the plant is expected to be fully operational in 2023.
“The investment is supported by a strong market demand, strong pipeline and underlines Space Peptides’ continuing commitment to serving the peptide pharmaceutical market across scales”, says Dr. Runze He, CEO of Space Peptides.